Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease

doi:10.4251/wjgo.v13.i8.772

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

(210)

(231)

(0)

(13)

(5)

(6149)

(14)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastrointest Oncol. Aug 15, 2021; 13(8): 772-798
Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.772

Table 5 Selected retrospective studies reporting prevalence of gastrointestinal immune-related adverse events in inflammatory bowel disease patients treated with all immune checkpoint inhibitor regimens

Ref.	Number of IBD patients	Single or multi center	Prevalence of GI irAE (%)
Abu-Sbeih et al[112], 2020	102	Multi	41.2
Grover et al[113], 2020	21	Single	28.0
Braga Neto et al[114], 2021	13	Single	30.7
Meserve et al[115], 2021	193 across 12 studies	Meta-analysis	40.0

IBD: Inflammatory bowel disease; GI: Gastrointestinal; irAE: Immune-related adverse events.

Full Size Table

Citation: Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798
URL: https://www.wjgnet.com/1948-5204/full/v13/i8/772.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i8.772

Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.